Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

269
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
269
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inflammation-associated alterations in mGluR transcript expression in the human nucleus accumbens independent of schizophrenia diagnosis.

Schizophrenia research·2026
Same author

ALS-FTD-linked CCNF<sup>S621G</sup> drives increased hippocampal astrocyte ramification and mitochondrial dysfunction and impairs motor neuron excitability.

Journal of neuroinflammation·2026
Same author

Genetic risk for schizophrenia modulates WIN 55,212-2 reward: Evidence from a heterozygous transmembrane domain neuregulin 1 mutant mouse model.

Psychopharmacology·2026
Same author

Combining cannabidiol and delta-9-tetrahydrocannabinol at a 50:3 ratio - a new therapeutic strategy for APP<sub>Swe</sub>/PS1ΔE9 transgenic mice?

Neurobiology of aging·2026
Same author

Effects of Chronic 100 mg/kg Cannabidiol Treatment in Male Double Transgenic <i>APP<sub>Swe</sub>/PS1∆E9</i> Mice.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

NF-κB pathway gene expression is elevated in the midbrain of people with high-inflammation schizophrenia.

Brain, behavior, and immunity·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Drug Development.

Carla Lucia Wahlich1, Tim Karl2

  • 1Friedrich-Alexander-University, Erlangen, Bavaria, Germany.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 25, 2025
PubMed
Summary
This summary is machine-generated.

This study investigated the effects of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) on Alzheimer's disease (AD) mouse models. Long-term CBD:THC treatment showed subtle therapeutic benefits for tauopathy-related behaviors, suggesting potential for multi-cannabinoid therapy in AD.

More Related Videos

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

Related Experiment Videos

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

Area of Science:

  • Neuroscience
  • Pharmacology
  • Genetics

Background:

  • Alzheimer's disease (AD) therapies have limited success, necessitating alternative treatments.
  • Cannabinoids, like cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), possess anti-inflammatory properties and are well-tolerated.
  • The combined effect of CBD and THC on tau pathology, a key feature of AD, remains poorly understood.

Purpose of the Study:

  • To evaluate the effects of chronic CBD and THC co-treatment on disease-relevant behaviors in female TAU58/2 transgenic mice.
  • To investigate the therapeutic potential of a specific CBD:THC ratio (50:3 mg/kg/day) in an AD mouse model.
  • To explore the impact of cannabinoids on motor function, memory, anxiety, and sensorimotor gating in the context of tauopathy.

Main Methods:

  • Six-month-old female TAU58/2 transgenic mice and wild-type controls were treated with CBD+THC (50:3 mg/kg/day) or vehicle for five weeks.
  • Behavioral assessments, including motor function, spatial and social recognition memory, anxiety, and sensorimotor gating, were conducted after three weeks of treatment.
  • Data analysis focused on treatment and genotype effects on various behavioral tests.

Main Results:

  • TAU58/2 mice displayed deficits in motor function, sensorimotor gating, anxiety-like behavior, and spatial memory.
  • Chronic CBD:THC co-treatment significantly improved motor function and partially reduced anxiety-like behavior in transgenic mice.
  • Cannabinoids showed a trend toward improving spatial memory, though not statistically significant; social recognition and sensorimotor gating were unaffected.

Conclusions:

  • Long-term CBD:THC treatment (50:3 mg/kg/day) demonstrated subtle but promising therapeutic effects on tauopathy-related behaviors in middle-aged mice.
  • This study provides the first evidence for the therapeutic potential of CBD:THC co-treatment in addressing behavioral symptoms of tauopathy.
  • Findings suggest that multi-cannabinoid therapy, particularly specific ratios, may hold promise for AD treatment, warranting further investigation into underlying molecular mechanisms.